文献速递心脑血管急症

药物洗脱支架与裸金属支架在大隐静脉桥血管病变中的比较:双盲随机试验

Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.
PubMed 文献 · Lancet · 2018-05-11
一句话结论在自体大隐静脉桥血管新发病变置入支架的患者中,12个月随访显示药物洗脱支架与裸金属支架的靶血管失败率无显著差异。

DIVA试验为双盲随机对照试验,自25个美国退伍军人事务部中心纳入599例(数据可用597例)因大隐静脉桥血管新发病变(50-99%狭窄,直径2.25-4.5 mm)需经皮冠状动脉介入且计划使用栓塞保护装置的患者,1:1随机接受药物洗脱支架或裸金属支架。主要终点12个月靶血管失败(心源性死亡、靶血管心肌梗死或靶血管血运重建的复合终点)发生率药物洗脱支架组17%(51/292) vs 裸金属支架组19%(58/305),校正风险比0.92(95%CI 0.63-1.34,P=0.70)。主要终点各组分、严重不良事件及支架血栓组间差异均无统计学意义。作者认为,在美国等药物洗脱支架价格高的国家,该结果提示在桥血管病变中可使用费用较低的裸金属支架而不损害安全性和有效性。

要点

  • 在因大隐静脉桥血管新发病变行支架置入的患者中,12个月靶血管失败率药物洗脱支架组17%(51/292) vs 裸金属支架组19%(58/305),校正HR 0.92(95%CI 0.63-1.34,P=0.70),无显著差异。
  • 主要终点各组分(心源性死亡、靶血管心肌梗死、靶血管血运重建)、严重不良事件及支架血栓的组间差异均无统计学意义。
  • 作者认为,在药物洗脱支架价格高的国家,该结果提示桥血管病变可使用费用较低的裸金属支架而不损害安全性和有效性。
  • 研究入组在达到修订后目标样本量762例之前提前终止(实际随机599例,数据可用597例)。

适用人群与场景

  • 年龄至少18岁、至少一处有意义的大隐静脉桥血管新发病变(直径2.25-4.5 mm的桥血管50-99%狭窄)、需经皮冠状动脉介入且计划使用栓塞保护装置的患者。
  • 来自25个美国退伍军人事务部中心;患者平均年龄68.6岁(SD 7.6),595例(>99%)为男性。

诊断标准与关键阈值

  • 有意义的大隐静脉桥血管新发病变定义为直径2.25-4.5 mm的桥血管50-99%狭窄。
  • 主要终点靶血管失败定义为心源性死亡、靶血管心肌梗死或靶血管血运重建的复合终点,评估12个月发生率。

研究设计与关键结果

  • 双盲随机对照试验,25个美国退伍军人事务部中心,随机599例、数据可用597例,1:1随机接受药物洗脱支架或裸金属支架。
  • 12个月靶血管失败发生率:药物洗脱支架组17%(51/292) vs 裸金属支架组19%(58/305),校正风险比0.92(95%CI 0.63-1.34,P=0.70)。
  • 主要终点各组分、严重不良事件及支架血栓的组间差异均无统计学意义。
  • 入组在达到修订后目标样本量762例之前提前终止。

证据类型、等级与局限

  • 证据类型:双盲随机对照试验(DIVA试验,ClinicalTrials.gov NCT01121224)。
  • 作者结论:在大隐静脉桥血管新发病变置入支架的患者中,12个月随访未发现药物洗脱支架与裸金属支架的结局有显著差异。
  • 局限:入组在达到修订后目标样本量762例之前提前终止。

对床旁实践的改变

  • 作者认为,研究结果在美国等药物洗脱支架价格高的国家有重要经济意义,提示桥血管病变可使用费用较低的裸金属支架而不损害安全性和有效性。
  • 适用人群为计划使用栓塞保护装置、因大隐静脉桥血管新发病变行经皮冠状动脉介入的患者。

指南或共识出处

  • DIVA试验(ClinicalTrials.gov NCT01121224),发表于Lancet,资助方为美国退伍军人事务部合作研究计划。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Few studies have examined the efficacy of drug-eluting stents (DES) for reducing aortocoronary saphenous vein bypass graft (SVG) failure compared with bare-metal stents (BMS) in patients undergoing stenting of de-novo SVG lesions. We assessed the risks and benefits of the use of DES versus BMS in de-novo SVG lesions.

METHODS: Patients were recruited to our double-blind, randomised controlled trial from 25 US Department of Veterans Affairs centres. Eligible participants were aged at least 18 years and had at least one significant de-novo SVG lesion (50-99% stenosis of a 2·25-4·5 mm diameter SVG) requiring percutaneous coronary intervention with intent to use embolic protection devices. Enrolled patients were randomly assigned, in a 1:1 ratio, by phone randomisation system to receive a DES or BMS. Randomisation was stratified by presence or absence of diabetes and number of target SVG lesions requiring percutaneous coronary intervention (one or two or more) within each participating site by use of an adaptive scheme intended to balance the two stent type groups on marginal totals for the stratification factors. Patients, referring physicians, study coordinators, and outcome assessors were masked to group allocation. The primary endpoint was the 12-month incidence of target vessel failure, defined as the composite of cardiac death, target vessel myocardial infarction, or target vessel revascularisation. The DIVA trial is registered with ClinicalTrials.gov, number NCT01121224.

FINDINGS: Between Jan 1, 2012, and Dec 31, 2015, 599 patients were randomly assigned to the stent groups, and the data for 597 patients were used. The patients' mean age was 68·6 (SD 7·6) years, and 595 (>99%) patients were men. The two stent groups were similar for most baseline characteristics. At 12 months, the incidence of target vessel failure was 17% (51 of 292) in the DES group versus 19% (58 of 305) in the BMS group (adjusted hazard ratio 0·92, 95% CI 0·63-1·34, p=0·70). Between-group differences in the components of the primary endpoint, serious adverse events, or stent thrombosis were not significant. Enrolment was stopped before the revised target sample size of 762 patients was reached.

INTERPRETATION: In patients undergoing stenting of de-novo SVG lesions, no significant differences in outcomes between those receiving DES and BMS during 12 months of follow-up were found. The study results have important economic implications in countries with high DES prices such as the USA, because they suggest that the lower-cost BMS can be used in SVG lesions without compromising either safety or efficacy.

FUNDING: US Department of Veterans Affairs Cooperative Studies Program.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Brilakis ES, Edson R, Bhatt DL, et al. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. Lancet. 2018. PMID: 29759512. doi:10.1016/S0140-6736(18)30801-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。